In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orqis Gains Momentum with Congestive Heart Failure Device

Executive Summary

Orqis Medical slid in under the wire to present late-breaking clinical results for a landmark trial in congestive heart failure at the American College of Cardiology meeting in Chicago in April. Relative to the trial's design, the results were somewhat mixed. The company failed to meet its clinical trial endpoints, but demonstrated significant improvements in a very sick acute heart failure population in a first-of-its kind study, and therefore, proof-of-principle of its novel approach. So, what appears at first glance to be bad news, is actually pretty good news.

Related Content

Interventional Heart Failure
Interventional Heart Failure
The Cardio-Renal Connection


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts